CAMBRIDGE, Mass., March 11, 2026
Vima Therapeutics has announced a major milestone in its drug development pipeline, confirming that the first patient has been dosed in its Phase 2 clinical trial for isolated dystonia using the investigational oral therapy VIM0423, while also extending its Series A financing to $100 million.
The funding round, including a new $40 million investment, brings total Series A financing to $100 million and will support two Phase 2 clinical trials evaluating VIM0423 for isolated dystonia and Parkinson’s disease. The financing included participation from Frazier Life Sciences along with existing investors Atlas Venture, Access Industries, and Canaan Partners. The company expects to initiate the Parkinson’s disease Phase 2 trial in mid-2026, with topline results from both clinical trials anticipated in the first half of 2027, positioning the company to advance a potential first-in-class oral therapy designed to address the underlying causes of movement disorders.
Phase 2 Clinical Development Advances for VIM0423
The announcement marks an important step in the clinical development of VIM0423, a once-daily investigational oral medicine designed to selectively target muscarinic cholinergic receptors in the brain, a biological pathway linked to abnormal signaling in movement disorders. The Stride Dystonia Phase 2 clinical trial is currently underway and aims to evaluate the therapy’s safety and efficacy in patients with isolated dystonia, a neurological condition characterized by involuntary muscle contractions that affect movement and posture.
Dystonia affects more than 160,000 people in the United States, while Parkinson’s disease impacts over one million Americans, highlighting the significant unmet medical need for improved treatment options. Vima Therapeutics founder and chief executive officer Bernard Ravina stated that the company’s early clinical results provide strong confidence in the therapeutic potential of VIM0423, emphasizing that both dystonia and Parkinson’s disease are linked to imbalances between dopamine and acetylcholine signaling in the brain. By targeting this biological pathway, the therapy is designed to restore balance in neural signaling and improve motor control in patients living with movement disorders.
Advertisement
Positive Phase 1 Data Supports Continued Development
The Phase 2 clinical program builds upon encouraging results from a completed Phase 1 study, which evaluated pharmacokinetics, safety, tolerability, and dose escalation of VIM0423 in both healthy volunteers and individuals diagnosed with dystonia. According to the company, the two-part Phase 1 trial demonstrated that VIM0423 was safe and well tolerated across single- and multiple-dose cohorts, with participants maintaining tolerability even when doses exceeded target therapeutic levels over a 28-day treatment period.
The study also achieved the desired exposure levels required to influence the underlying biological mechanisms driving dystonia, supporting the decision to advance the drug candidate into Phase 2 trials. Experts in neurology have welcomed the development of a potential oral therapy for dystonia, noting that existing treatment options often involve invasive procedures such as injections or deep brain stimulation surgery, which can limit accessibility and patient comfort. The investigational therapy aims to provide a more convenient, non-invasive treatment option that could significantly improve quality of life for individuals affected by chronic movement disorders.
Investment Fuels Next Phase of Neurology Drug Innovation
The extended $100 million Series A financing is expected to play a key role in advancing the company’s clinical pipeline and expanding its research efforts in neurological diseases. The funding will support the completion of both Phase 2 trials while enabling Vima Therapeutics to further explore the potential of antimuscarinic compounds targeting central nervous system pathways associated with abnormal motor control.
VIM0423 has already received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of isolated dystonia, highlighting the urgent need for new therapies and the drug candidate’s potential to address significant unmet medical needs.
Vima Therapeutics has also established a collaboration with Children’s Mercy Kansas City, under which the company holds an exclusive worldwide license for methods and compositions related to the treatment of movement disorders using specific antimuscarinic compounds. As clinical development progresses, the company aims to establish VIM0423 as a first-in-class therapy capable of improving motor function and restoring control of movement in patients affected by dystonia and Parkinson’s disease, potentially transforming treatment approaches for these debilitating neurological conditions.
Source: Vima Therapeutics press release
